Data from the Centers for Disease Control and Prevention show people who received the Moderna COVID-19 vaccine have the lowest rates of infection and death compared to other recipients of other COVID shots, but all available vaccines provide strong protection.
While the Pfizer-BioNTech and Johnson & Johnson have somewhat higher incidence rates of breakthrough infections as of late August — the most recent date shown on the CDC’s data tracker — they both see significantly smaller infection rates than unvaccinated people, who were more than six times more likely to test positive for COVID-19 and over 11 times more likely to die from the illness.
Experts said the numbers could influence the decisions of those who are looking to take a booster shot, an extra jab authorized for those who need more protection, such as the elderly or those who are immunocompromised.
Dr. Ali Mokdad, a professor at the University of Washington’s Institute of Health Metrics and Evaluation, said those in the U.S. who received the J&J vaccine may want to consider getting an mRNA vaccine — the Moderna or Pfizer — for their booster, a so-called “mix and match” approach that was approved by the Food and Drug Administration last week.
Overall, Dr. Mokdad said, all the vaccines are highly effective, but the J&J vaccine is the most obvious candidate for those who are thinking of mixing vaccines when they get their booster.
“If you are on Johnson & Johnson in the United States, mRNA by far are better vaccines,” he said. “You should consider getting mRNA, although there’s less data on that.”
Read More
There is more data on getting a booster based on the vaccine originally taken by the patient. Dr. Mokdad, who received Pfizer for his initial doses, got the same vaccine when it was time for his booster, and many of his colleagues at the university did the same, he said.
As of Aug. 29, 2021, the incidence of COVID-19 cases per 100,000 people was 665.74 among the unvaccinated, according to the CDC. For those with Moderna shots, it was 86.63, and Pfizer was 125.77. Janssen, the vaccine developed by Johnson & Johnson, had an incidence of 150.39 per 100,000.
Deaths saw an even steeper drop among the vaccinated: while the unvaccinated saw 9.14 deaths per 100,000, those with Moderna had 0.47. Pfizer and J&J had respective incidences of 0.88 and 1.70.

The CDC said that data was gathered from 16 health departments representing 30% of the U.S. population, including Alabama, Florida, New York City and Utah. Pennsylvania was not cited in the data, but the CDC says the list will be updated as more jurisdictions participate.
The recommendation to potentially seek out a particular vaccine brand is somewhat different from what many experts were urging earlier in the year, which was to get whatever vaccine was available as soon as possible. Now that there are enough vaccines for everyone in the U.S. who wants one, and since there is more data about vaccine efficacy over time, there is more reason to be pickier, but that option doesn’t exist globally.
Because doses in some countries remain scarce compared to the U.S., or there may be fewer options to choose from, people overseas shouldn’t wait for one vaccine over another.
“When it comes to global, my recommendation is ... the best vaccine for you is the one available to you,” Dr. Mokdad said. “We want you to have immunity as soon as possible.”
Dr. Richard Zimmerman, a professor at the University of Pittsburgh’s school of medicine, said he was excited to get his Moderna booster so that he can go back to coaching Special Olympics athletics for his children.
He said he was enthusiastic that the data shows how much the boosters bring up titers — the amount of antibodies a person gets after vaccination — and that the delta variant appears generally unable to evade the protection given by the shots.
“That was such great news because that means I get to go back and coach Special Olympics and just do things,” he said. “I’m going to feel much safer in taking my kids to church, to community activities, to eating out — all those things — once we have our boosters in. And for my family, we have our boosters.”
He emphasized that young people with no underlying conditions are still likely to fare better with just about any vaccine, including two doses of the J&J shot when that demographic is authorized for boosters. Seniors or others with high risk may want to go more towards a “mixing strategy” if they received the Johnson & Johnson for their first dose.
There will always be people who are unvaccinated, Dr. Zimmerman said, but if 70% of people got their full vaccination and boosters when needed, we may finally see the pandemic become an endemic, or something like the common cold or flu.
“We’re boosting not just against the original, wild-type strain that the vaccines are created against,” Dr. Zimmerman said. “We’re boosting against the delta variant, and these antibody levels look great. These antibody levels should last.”
Mick Stinelli: mstinelli@post-gazette.com; 412-263-1869; and on Twitter: @MickStinelli







Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.